U.S. Markets closed

Gene Biotherapeutics, Inc. (CRXM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0400-0.0030 (-6.98%)
At close: 3:52PM EDT

Gene Biotherapeutics, Inc.

11568 Sorrento Valley Road
Suite 14
San Diego, CA 92121
United States

Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher J. ReinhardCo-Founder, CEO, Pres, Treasurer, Sec. & Director164.31kN/A1954
Mr. Duane LinstromGen. Counsel119.23kN/AN/A
Mr. James L. GrainerChairman, CFO & Sec.N/AN/A1955
Dr. Lois A. ChandlerChief Operating OfficerN/AN/AN/A
Dr. Ronald J. ShebuskiChief Scientific OfficerN/AN/AN/A
Mr. Kelly D. ScottVP of Bus. Devel. of Medtech Bus. Unit and EVP of Inner Cool Therapies IncN/AN/A1956
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Gene Biotherapeutics, Inc. manages a portfolio of medical technologies in the United States. It focuses on acquiring and developing gene-based therapeutics. The company, through its subsidiary, Angionetics, Inc., focuses on the clinical advancement and commercialization of Generx, an interventional cardiology, angiogenic gene therapy Phase 3 product candidate designed for the potential treatment of patients with refractory angina due to advanced coronary artery disease. It also holds royalties on the commercialization of Excellagen technology platform for advanced wound care in Eurasian countries. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Corporate Governance

Gene Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.